Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

Table 5 Backward logistic regression of factors involved in nevirapine induced liver toxicity

	OR (95%CI)	p	aOR (95%CI)	p
Male vs Female	0.19 (0.04–0.94)	0.042	0.27 (0.06–1.30)	0.102
Age (× 1 year more)	0.96 (0.88–1.04)	0.293	–
MSM vs HE	0.24 (0.01–4.51)	0.338	–
IVDUs vs HE	2.20 (0.58–8.41)	0.247	–
Other vs HE	1.36 (0.06–29.16)	0.844	–
Caucasian vs Non-Caucasian	0.67 (0.08–5.64)	0.714	–
BMI (× 1 more)	0.70 (0.51–0.94)	0.020	0.72 (0.52–1.00)	0.050
Previous AIDS	0.67 (0.08–5.56)	0.713	–
Previous therapy duration (× 1 year more)	1.05 (0.90–1.23)	0.518	–
CD4 200–500 cell/μL vs < 200 cell/μL	1.17 (0.05–25.7)	0.920	1.51 (0.07–32.23)	0.790
CD4 > 500 cell/μL vs < 200 cell/μL	3.97 (0.21–74.51)	0.357	8.12 (0.42–156.90)	0.166
HIV-RNA (× 1 log10 more)	0.80 (0.54–1.18)	0.260	–
AST (× 1 more)	1.02 (1.01–1.03)	0.008	1.01 (0.99–1.03)	0.144
ALT (× 1 more)	1.01 (1.00–1.02)	0.015	–
HCV coinfection	6.93 (1.38–34.87)	0.019	8.00 (1.27–50.29)	0.027
HBV coinfection	2.39 (0.28–20.36)	0.427	–
ARV Backbone: AZT/DDI/D4T vs ABC	0.73 (0.12–4.47)	0.731	–
ARV Backbone: TDF vs ABC	0.12 (0.01–3.141)	0.204	–
ARV Backbone: Other vs ABC	0.49 (0.02–13.47)	0.672	–
ABCB1 rs1045642 CT/TT vs CC	0.18 (0.04–0.76)	0.020	0.10 (0.02–0.47)	0.004

Abbreviations: OR Odds Ratio, aOR adjusted Odds Ratio, CI confidence interval, HE Heterosexual, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate, BMI Body Mass Index, ABCB ATP Binding Cassette Subfamily B

ISSN: 1471-2334